OB Mobile Logo

Search form


Treating VVA: Objective and Subjective Measure of Benefit

Treating VVA: Objective and Subjective Measure of Benefit

Drug therapies for symptoms related to genituourinary syndrome of menopause (GSM) tend to have narrow indications of use. Ospemifene, for example, has been approved for the treatment of dyspareunia, or painful sex, in postmenopausal women. But new research shows that it may have additional benefits as well.

In this video, David Portman, MD, of the Columbus Center for Women's Health Research, Columbus, Ohio, discusses the research, which shows that ospemifene is associated not only with improvements in symptoms of dyspareunia but also with improvements of a woman's "most bothersome" symptom of menopause, whatever she defines that to be.

This research was presented in October 2014 at the 25th Annual Meeting of The North American Menopause Society.

Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.